Advertisement

How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach

  • Ali RezaieEmail author
  • Mark Pimentel
  • Satish S. Rao
Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract

Abstract

Small intestinal bacterial overgrowth (SIBO) is characterized by an excessive amount of bacteria in the small intestine and a constellation of symptoms that include bloating, pain, gas, and diarrhea. Although known for many decades, there is a lack of consensus and clarity regarding the natural history and methods for its diagnosis. Several tests have been proposed, including the glucose breath test, lactulose breath test, small intestinal aspiration and culture, and others. However, there is a lack of standardization of these tests and their interpretation. Treatment of SIBO remains empirical; generally, broad spectrum antibiotics are recommended for 2 weeks (amoxicillin, rifaximin, ciprofloxacin, etc.) but evidence for their use is fair. Clearly, there is a strong need to develop a systematic approach for the management of SIBO and to perform multicenter clinical trials for the treatment of SIBO. In this review, we will discuss the current evidence for the diagnosis and treatment of SIBO, which includes (1) elimination/modification of the underlying causes, (2) induction of remission (antibiotics and elemental diet), and (3) maintenance of remission (promotility drugs, dietary modifications, repeat or cyclical antibiotics).

Keywords

Small intestinal bacterial overgrowth (SIBO) Glucose breath test Lactulose breath test Small intestinal aspiration and culture Antibiotics Elemental diet Promotility drugs 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ali Rezaie reports support from the following sources for teaching, research, and consultation, outside the submitted work: Commonwealth Laboratories, Actavis, and Salix Pharmaceuticals. Mark Pimentel reports support from the following sources for teaching, research, and consultation, outside the submitted work: Commonwealth Laboratories, Salix Pharmaceuticals, Entera Health, Synthetic Biologics, Synthetic Biologics, Micropharma, and Naia Pharmaceuticals. Satish Rao reports support from the following sources for teaching, research, and consultation, outside the submitted work: Forest Laboratories, Hollister, Ironwood Pharmaceuticals, Sucampo Pharmaceuticals, In Control Medical, Vibrant, American Medical Systems, Sun Sweet Corporation, Synergy Pharmaceuticals, Salix Pharmaceuticals, and Ventrus Laboratories.

Human and Animal Rights and Informed Consent

With regard to the authors’ research cited in this paper, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chron Dis. 2013;4:223–31.CrossRefGoogle Scholar
  2. 2.
    Gutierrez IM, Kang KH, Calvert CE, et al. Risk factors for small bowel bacterial overgrowth and diagnostic yield of duodenal aspirates in children with intestinal failure: a retrospective review. J Pediatr Surg. 2012;47:1150–4.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978–90.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol. 2010;44:672–5.CrossRefPubMedGoogle Scholar
  5. 5.••
    Jacobs C, Coss Adame E, Attaluri A, et al. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37:1103–11. This study showed that abscent phase III MMCs is a risk factor for bacterial overgrowth.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Husebye E, Skar V, Hoverstad T, et al. Abnormal intestinal motor patterns explain enteric colonization with gram-negative bacilli in late radiation enteropathy. Gastroenterology. 1995;109:1078–89.CrossRefPubMedGoogle Scholar
  8. 8.
    Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci. 2010;6:49–55.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6:759–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Giamarellos-Bourboulis E, Tang J, Pyleris E, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50:1076–87.Google Scholar
  11. 11.
    Yang CY, Chang CS, Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol. 1998;33:867–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98:1362–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Basseri RJ, Basseri B, Pimentel M, et al. Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol (N Y). 2012;8:22–8.Google Scholar
  14. 14.
    George NS, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. Dig Dis Sci. 2014;59:645–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol. 2015;21:10609–20.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Pimentel M, Wallace D, Hallegua D, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis. 2004;63:450–2.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Signoretti M, Stigliano S, Valente R, et al. Small intestinal bacterial overgrowth in patients with chronic pancreatitis. J Clin Gastroenterol. 2014;48 Suppl 1:S52–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Strid H, Simren M, Stotzer PO, et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67:129–37.CrossRefPubMedGoogle Scholar
  19. 19.
    Patricio Ibanez MP, Melmed GY, Ippoliti A, Targan SR, Vasiliauskas EA. Fatigue and abdominal bloating predict small intestinal bacterial overgrowth (SIBO) in patients with ulcerative colitis (UC). Gastroenterology. 2008;134:A-350.Google Scholar
  20. 20.
    Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38:674–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53:1443–54.CrossRefPubMedGoogle Scholar
  22. 22.••
    Baker JC, Saad WRJ. Common gastrointestinal symptoms do not predict the results of glucose breath testing in the evaluation of suspected small intestinal bacterial overgrowth. Am J Gastroenterol. 2015;110:S1004. Using a large database of breath tests, this study showed that bacterial overgrowth cannot be predicted by symptoms.Google Scholar
  23. 23.
    Levitt MD, Bond Jr JH. Volume, composition, and source of intestinal gas. Gastroenterology. 1970;59:921–9.PubMedGoogle Scholar
  24. 24.
    Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55:297–303.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.•
    Rezaie ACK, Chang C, Kemmerly T, Pimentel M. Methane on breath test predicts altered rectal sensation during high resolution anorectal manometry. Gastroenterology. 2014;146:S-721. This study showed that visceral sensitivity assessed by graded rectal balloon distension has direct correlation with bacterial overgrowth.CrossRefGoogle Scholar
  26. 26.
    Kunkel D, Basseri RJ, Makhani MD, et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56:1612–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Chatterjee S, Park S, Low K, et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007;102:837–41.CrossRefPubMedGoogle Scholar
  28. 28.••
    Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27:481–9. This study showed that glucose breath test has 84% specificity and 42% sensitivity in diagnosis of SIBO as compared to duodenal aspiration.CrossRefPubMedGoogle Scholar
  29. 29.
    Erdogan A, Lee YY, Badger C, Hall P, O'Banion M, Rao SSC. What is the optimal threshold for an increase in hydrogen and methane levels with glucose breath test (GBT) for detection of small intestinal bacterial overgrowth (SIBO)? Gastroenterology. 2014;146(Supplement 1):S-532.CrossRefGoogle Scholar
  30. 30.
    Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95:3503–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–9.PubMedGoogle Scholar
  33. 33.
    Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Euro Rev Med Pharmacol Sci. 2009;13:111–6.Google Scholar
  34. 34.
    Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engle J Med. 2011;364:22–32.CrossRefGoogle Scholar
  35. 35.
    Lacy BE, Chey WD, Lembo AJ. New and emerging treatment options for irritable bowel syndrome. Gastroenterol Hepatol (N Y). 2015;11:1–19.Google Scholar
  36. 36.
    Pourmorady JS, Rezaie E, Pimentel MA. Breath testing for small intestinal bacterial overgrowth in irritable bowel syndrome: a meta-analysis. Am J Gastroenterol. 2015;110:S762.Google Scholar
  37. 37.
    Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44:547–50.PubMedGoogle Scholar
  38. 38.••
    Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59:1278–85. This randomized controlled trial showed that combination of rifaximin and neomycin is more effective than neomycin alone in treatment of constipation associated with methane-predominat SIBO.CrossRefPubMedGoogle Scholar
  39. 39.
    Gottlieb K, Wacher V, Sliman J, Pimentel M. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther. 2015;43(2):197–212.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Triantafyllou K, Chang C, Pimentel M. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil. 2014;20:31–40.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Winitz M, Adams RF, Seedman DA, et al. Studies in metabolic nutrition employing chemically defined diets. II. Effects on gut microflora populations. Am J Clin Nutr. 1970;23:546–59.PubMedGoogle Scholar
  42. 42.
    Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004;49:73–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Chedid V, Dhalla S, Clarke JO, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3:16–24.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Logan AC, Beaulne TM. The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: a case report. Altern Med Rev. 2002;7:410–7.PubMedGoogle Scholar
  45. 45.
    Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008;103:2031–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Code CF, Marlett JA. The interdigestive myo-electric complex of the stomach and small bowel of dogs. J Physiol. 1975;246:289–309.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977;59:1158–66.PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Pimentel M, Soffer EE, Chow EJ, et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639–43.CrossRefPubMedGoogle Scholar
  49. 49.
    Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9:271–85.CrossRefPubMedGoogle Scholar
  50. 50.
    Nasr I, Rao SS, Attaluri A, et al. Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study. Indian J Gastroenterol. 2009;28:136–42.CrossRefPubMedGoogle Scholar
  51. 51.
    Madrid AM, Hurtado C, Venegas M, et al. Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96:1251–5.CrossRefPubMedGoogle Scholar
  52. 52.
    Pimentel M, Morales W, Lezcano S, et al. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009;5:435–42.Google Scholar
  53. 53.
    Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93–100.CrossRefPubMedGoogle Scholar
  54. 54.
    Law D, Conklin J, Pimentel M. Lactose intolerance and the role of the lactose breath test. Am J Gastroenterol. 2010;105:1726–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Rao SS, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:1256–70.CrossRefPubMedGoogle Scholar
  56. 56.
    Peppin J, Pappagallo M, Barrett A, et al. Effect of subcutaneous methylnaltrexone on patient-reported outcomes in advanced illness patients with opioid-induced constipation. J Pain. 2013;1:S62.CrossRefGoogle Scholar
  57. 57.
    Chey W, Tack J, Webster L, et al. Naloxegol symptom responder rates in patients with opioid-induced constipation: results from two prospective, randomized controlled trials. Am J Gastroenterol. 2013;108:S570.Google Scholar
  58. 58.
    Sloots CEJ, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55:2912–21.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Spierings EL, Drossman DA, Cryer BL, et al. A pooled analysis of response to lubiprostone in patients with opioid-induced constipation receiving non-methadone opioids versus methadone. Gastroenterology. 2014;1:S-360.CrossRefGoogle Scholar
  60. 60.
    Hwang HJ, An MS, Ha TK et al. All the commercially available adhesion barriers have the same effect on adhesion prophylaxis? A comparison of barrier agents using a newly developed, severe intra-abdominal adhesion model. Int J Colorectal Dis 2013;28:1117–1125.Google Scholar
  61. 61.
    Reinstein E, Pimentel M, Pariani M, et al. Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: presentation of a rare manifestation and review of the literature. Eur J Med Genet. 2012;55:548–51.PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Raj SR, Black BK, Biaggioni I, et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111:2734–40.CrossRefPubMedGoogle Scholar
  63. 63.
    Madsbad S. A review of head-to-head comparisons of GLP-1 receptor agonists. Diabetes Obes Metab. 2015;6(1):19–28.Google Scholar
  64. 64.
    Ockeloen LE, Deckers-Kocken JM. Short- and long-term effects of a lactose-restricted diet and probiotics in children with chronic abdominal pain: a retrospective study. Complement Ther Clin Pract. 2012;18:81–4.CrossRefPubMedGoogle Scholar
  65. 65.
    Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382:1249–57.CrossRefPubMedGoogle Scholar
  66. 66.
    Rezaie A, Pimentel M. Probiotics for antibiotic-associated diarrhea: PLACIDE swings the pendulum. Gastroenterology. 2014;146:1822–3.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.GI Motility Program, Division of Gastroenterology, Department of MedicineCedars-Sinai Medical CenterLos AngelesUSA
  2. 2.Division of Gastroenterology/Hepatology, Medical College of GeorgiaAugusta UniversityAugustaUSA
  3. 3.David Geffen School of Medicine at University of California, Los Angeles (UCLA)Los AngelesUSA

Personalised recommendations